Back to News
Market Impact: 0.15
Keymed Biosciences annonce ses résultats pour le premier semestre 2026 et fait le point sur ses activités
Source: PR Newswire
Corporate EarningsCompany FundamentalsHealthcare & Biotech
Keymed Biosciences reported 1H26 (ended 30 June 2026) total revenue of 617 million RMB, with its flagship product Kangyueda cited as generating revenue (figures not provided in the excerpt). The release appears primarily informational, with no profit, growth, or guidance numbers included here. Overall, impact is likely limited absent further details on margins and outlook.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
More News
- Bending Spoons wants to revive software castoffs. Berkshire is backing the plan
- SpaceX’s ambitious, expensive gamble to replace AT&T, T-Mobile, and Verizon
- Japan puts up to $21bn into two GlobalFoundries chip fabs in New York
- These tech stocks are a buy ahead of their earnings reports, Bank of America says
- Alphabet’s chief investment officer responds to Jefferies warning that the most likely outcome of the AI boom is massive U.S. capital destruction
- A 44-minute call and a memo: How Alexandr Wang won Mark Zuckerberg’s trust—and a $100 billion-plus AI bet